CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Inovio Pharmaceuticals, Inc. - INO CFD

    0.3675
    2.08%
    0.0400
    Low: 0.3575
    High: 0.3783
    Market Trading Hours* (UTC) Opens on Monday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0400
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Inovio Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.36
    Open* 0.3599
    1-Year Change* -80.12%
    Day's Range* 0.3575 - 0.3783
    52 wk Range 0.38-2.61
    Average Volume (10 days) 2.11M
    Average Volume (3 months) 140.51M
    Market Cap 120.74M
    P/E Ratio -100.00K
    Shares Outstanding 268.08M
    Revenue 9.62M
    EPS -0.66
    Dividend (Yield %) N/A
    Beta 0.97
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 29, 2023 0.3675 0.0075 2.08% 0.3600 0.3783 0.3575
    Sep 28, 2023 0.3600 -0.0060 -1.64% 0.3660 0.3677 0.3535
    Sep 27, 2023 0.3611 0.0006 0.17% 0.3605 0.3650 0.3570
    Sep 26, 2023 0.3576 -0.0077 -2.11% 0.3653 0.3658 0.3576
    Sep 25, 2023 0.3600 0.0000 0.00% 0.3600 0.3600 0.3500
    Sep 19, 2023 0.3900 0.0000 0.00% 0.3900 0.3900 0.3900
    Sep 18, 2023 0.3900 0.0000 0.00% 0.3900 0.3900 0.3900
    Sep 15, 2023 0.4000 -0.0100 -2.44% 0.4100 0.4100 0.4000
    Sep 14, 2023 0.3900 -0.0100 -2.50% 0.4000 0.4000 0.3900
    Sep 13, 2023 0.4100 -0.0100 -2.38% 0.4200 0.4300 0.4100
    Sep 12, 2023 0.4300 -0.0100 -2.27% 0.4400 0.4400 0.4300
    Sep 11, 2023 0.4300 0.0000 0.00% 0.4300 0.4300 0.4300
    Sep 8, 2023 0.4300 -0.0100 -2.27% 0.4400 0.4400 0.4100
    Sep 7, 2023 0.4300 -0.0200 -4.44% 0.4500 0.4600 0.4200
    Sep 6, 2023 0.4100 -0.0200 -4.65% 0.4300 0.4300 0.4100
    Sep 5, 2023 0.4300 0.0000 0.00% 0.4300 0.4400 0.4200
    Sep 1, 2023 0.4300 0.0000 0.00% 0.4300 0.4400 0.4300
    Aug 31, 2023 0.4300 0.0000 0.00% 0.4300 0.4400 0.4300
    Aug 30, 2023 0.4300 0.0000 0.00% 0.4300 0.4300 0.4200
    Aug 29, 2023 0.4300 0.0200 4.88% 0.4100 0.4300 0.4100

    Inovio Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Inovio Pharmaceuticals Inc Earnings Release
    Q3 2023 Inovio Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, February 28, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Inovio Pharmaceuticals Inc Earnings Release
    Q4 2023 Inovio Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 10.2623 1.77476 7.41122 4.11193 30.4819
    Revenue 10.2623 1.77476 7.41122 4.11193 30.4819
    Total Operating Expense 277.836 302.993 126.787 115.22 124.573
    Selling/General/Admin. Expenses, Total 90.1853 53.7523 37.2478 27.2032 29.3152
    Research & Development 187.65 249.24 94.2454 88.0173 95.2579
    Unusual Expense (Income) 0 0 -4.70606 0 0
    Operating Income -267.574 -301.218 -119.376 -111.109 -94.0911
    Interest Income (Expense), Net Non-Operating -6.21775 -2.34978 -42.8094 -10.1968 -0.70688
    Net Income Before Taxes -277.653 -303.224 -162.89 -120.809 -94.798
    Net Income After Taxes -277.653 -303.224 -162.89 -120.552 -96.9678
    Minority Interest 0 0 1.06376 1.19256
    Net Income Before Extra. Items -279.818 -303.659 -166.411 -119.359 -96.9678
    Net Income -279.818 -303.659 -166.411 -119.359 -96.9678
    Income Available to Common Excl. Extra. Items -279.818 -303.659 -166.411 -119.359 -96.9678
    Income Available to Common Incl. Extra. Items -279.818 -303.659 -166.411 -119.359 -96.9678
    Diluted Net Income -279.818 -303.659 -166.411 -119.359 -96.9678
    Diluted Weighted Average Shares 238.622 208.83 155.127 98.718 92.54
    Diluted EPS Excluding Extraordinary Items -1.17264 -1.4541 -1.07274 -1.20909 -1.04785
    Diluted Normalized EPS -1.17264 -1.4541 -1.10308 -1.20909 -1.04785
    Total Extraordinary Items
    Other, Net -3.86158 0.34337 -0.7049 0.4962
    Equity In Affiliates -2.16521 -0.43439 -4.58461
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.22597 0.11494 0.12467 9.15413 0.7844
    Revenue 0.22597 0.11494 0.12467 9.15413 0.7844
    Total Operating Expense 37.2671 44.0671 56.0708 44.9112 104.922
    Selling/General/Admin. Expenses, Total 13.5231 13.8906 13.9509 11.824 48.4568
    Research & Development 21.744 30.1765 42.1199 33.0871 56.4649
    Operating Income -37.0411 -43.9522 -55.9462 -35.757 -104.137
    Interest Income (Expense), Net Non-Operating 2.93443 5.72854 4.2473 -1.08608 -4.35694
    Other, Net -1.42787 -2.42568 -2.76429 -0.94078 -0.00305
    Net Income Before Taxes -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Net Income After Taxes -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Minority Interest 0
    Equity In Affiliates 0 0 0 0 0
    Net Income Before Extra. Items -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Net Income -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Income Available to Common Excl. Extra. Items -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Income Available to Common Incl. Extra. Items -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Diluted Net Income -35.5345 -40.6493 -54.4631 -37.7839 -108.497
    Diluted Weighted Average Shares 264.354 258.438 250.585 249.351 235.278
    Diluted EPS Excluding Extraordinary Items -0.13442 -0.15729 -0.21734 -0.15153 -0.46114
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.12685 -0.15729 -0.21734 -0.15153 -0.46114
    Unusual Expense (Income) 2 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 315.243 448.445 471.171 94.201 87.8148
    Cash and Short Term Investments 252.999 401.315 411.643 89.5341 81.2325
    Cash & Equivalents 46.3294 71.1438 250.728 22.1961 23.6936
    Short Term Investments 206.669 330.171 160.915 67.338 57.5388
    Total Receivables, Net 11.7382 8.03204 19.0637 2.03212 4.05494
    Accounts Receivable - Trade, Net 1.70173 5.46685 18.56 0.70007 3.31636
    Prepaid Expenses 50.5057 39.0982 40.4639 2.63474 2.5274
    Total Assets 348.533 495.941 539.772 143.952 131.113
    Property/Plant/Equipment, Total - Net 17.9562 29.0242 24.0894 26.556 15.949
    Property/Plant/Equipment, Total - Gross 39.5196 47.9686 40.083 39.7225 25.9489
    Accumulated Depreciation, Total -21.5634 -18.9444 -15.9936 -13.1665 -9.99992
    Goodwill, Net 10.5134 10.5134 10.5134 10.5134 10.5134
    Intangibles, Net 2.12986 2.62636 3.14677 3.69385 4.76015
    Long Term Investments 2.00714 3.9068 4.89475 6.31536 9.40591
    Other Long Term Assets, Total 0.68404 1.42579 25.9575 2.67202 2.67
    Total Current Liabilities 96.8681 65.7416 41.706 31.9893 35.2998
    Accounts Payable 19.8625 24.2137 0.82552 6.91908 10.0438
    Payable/Accrued 45.2204 0.54803 0.64297 0.72973 4.60189
    Accrued Expenses 29.2224 36.3611 32.658 17.4428 15.1386
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.5627 4.61885 7.57944 6.89777 5.51547
    Total Liabilities 126.171 96.2721 78.6317 140.516 44.1771
    Total Long Term Debt 16.6148 14.9597 18.6558 77.0229 0
    Deferred Income Tax 0.03205 0.03205 0.03205 0.03205 0.02477
    Minority Interest 0 1.96976 0.09627
    Other Liabilities, Total 12.6556 15.5387 18.2379 29.5025 8.75633
    Total Equity 222.363 399.669 461.141 3.4351 86.9361
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.25309 0.21738 0.18685 0.10136 0.09723
    Additional Paid-In Capital 1710.66 1609.59 1367.41 742.647 707.794
    Retained Earnings (Accumulated Deficit) -1487.85 -1209.86 -906.197 -739.786 -620.426
    Other Equity, Total -0.69874 -0.28224 -0.25615 0.47261 -0.52887
    Total Liabilities & Shareholders’ Equity 348.533 495.941 539.772 143.952 131.113
    Total Common Shares Outstanding 253.091 217.383 186.851 101.361 97.2258
    Total Preferred Shares Outstanding 0.00001 0.00001 0.00001 0.00002 0.00002
    Long Term Debt 16.6148 14.9597 18.6558 77.0229
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 233.896 315.243 350.208 416.185 399.907
    Cash and Short Term Investments 223.751 252.999 281.883 348.125 360.394
    Cash & Equivalents 28.2381 46.3294 21.9882 41.1019 59.0095
    Short Term Investments 195.513 206.669 259.895 307.023 301.384
    Total Receivables, Net 5.03511 11.7382 10.0807 11.3715 7.4908
    Accounts Receivable - Trade, Net 0.0733 1.70173 2.44287 4.48264 4.00368
    Prepaid Expenses 5.11017 50.5057 58.2442 56.6886 32.0223
    Total Assets 266.583 348.533 391.968 459.399 445.511
    Property/Plant/Equipment, Total - Net 16.8489 17.9562 26.1652 27.126 27.9484
    Goodwill, Net 10.5134 10.5134 10.5134 10.5134 10.5134
    Intangibles, Net 2.04778 2.12986 2.24944 2.36903 2.49959
    Long Term Investments 2.62378 2.00714 2.12999 2.43505 3.36907
    Other Long Term Assets, Total 0.65252 0.68404 0.70199 0.77014 1.2738
    Total Current Liabilities 55.1511 96.8681 94.9147 131.064 59.3597
    Payable/Accrued 1.41727 80.9073 75.7816 106.354 39.5228
    Accrued Expenses 21.9336 13.3981 16.3067 12.8605 14.5007
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 4.211 2.5627 2.82645 11.8495 5.33615
    Total Liabilities 67.369 126.171 125.271 161.728 90.4261
    Total Long Term Debt 0 16.6148 16.3013 16.5214 16.2079
    Long Term Debt 0 16.6148 16.3013 16.5214 16.2079
    Deferred Income Tax 0.03205 0.03205 0.03205 0.03205 0.03205
    Other Liabilities, Total 12.1859 12.6556 14.0227 14.1104 14.8265
    Total Equity 199.214 222.363 266.697 297.671 355.085
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.26274 0.25309 0.24948 0.2475 0.22651
    Additional Paid-In Capital 1728.03 1710.66 1700.72 1693.67 1642.42
    Retained Earnings (Accumulated Deficit) -1528.5 -1487.85 -1433.38 -1395.6 -1287.1
    Other Equity, Total -0.5828 -0.69874 -0.88521 -0.64966 -0.45789
    Total Liabilities & Shareholders’ Equity 266.583 348.533 391.968 459.399 445.511
    Total Common Shares Outstanding 262.739 253.091 249.485 247.505 226.511
    Total Preferred Shares Outstanding 0.00001 0.00001 0.00001 0.00001 0.00001
    Accounts Payable 11.1944
    Current Port. of LT Debt/Capital Leases 16.3948
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -279.818 -303.659 -167.475 -120.552 -96.9678
    Cash From Operating Activities -216.215 -215.709 -177.979 -97.8501 -73.5502
    Cash From Operating Activities 3.65671 3.0401 3.039 3.59839 3.74718
    Amortization 0.49649 0.52042 0.54708 1.06629 1.24958
    Deferred Taxes 0 0 0.0054 0
    Non-Cash Items 39.6153 34.0382 56.9816 21.5747 13.3131
    Changes in Working Capital 19.8342 50.3515 -71.0718 -3.54312 5.10778
    Cash From Investing Activities 109.586 -175.344 -58.7957 -9.045 42.4199
    Capital Expenditures -0.96915 -1.23101 -1.52067 -0.98793 -2.08502
    Other Investing Cash Flow Items, Total 110.555 -174.113 -57.2751 -8.05707 44.5049
    Cash From Financing Activities 81.8407 211.499 465.28 105.398 31.0373
    Financing Cash Flow Items 0 0 2.37997 -0.35463 0
    Issuance (Retirement) of Stock, Net 81.8407 211.499 462.728 8.3086 31.0373
    Foreign Exchange Effects -0.02556 -0.03013 0.02721
    Net Change in Cash -24.8144 -179.584 228.532 -1.49754 -0.09295
    Cash Interest Paid 1.06698 1.0778 4.62476 2.71759
    Issuance (Retirement) of Debt, Net 0 0 0.17162 97.4436
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -40.6493 -279.818 -225.355 -187.571 -79.0737
    Cash From Operating Activities -36.6645 -216.215 -179.875 -112.41 -61.8821
    Cash From Operating Activities 0.70738 3.65671 2.77667 1.86996 0.92938
    Amortization 0.08208 0.49649 0.37691 0.25733 0.12677
    Non-Cash Items 1.7177 39.6153 35.4049 29.4844 15.7913
    Cash Interest Paid 0.53349 1.06698 1.06698 0.53349 0.53349
    Changes in Working Capital 1.47767 19.8342 6.92106 43.5492 0.3442
    Cash From Investing Activities 18.9999 109.586 55.585 11.0283 21.3323
    Capital Expenditures -0.29698 -0.96915 -0.80404 -0.71721 0
    Other Investing Cash Flow Items, Total 19.2969 110.555 56.3891 11.7456 21.3323
    Cash From Financing Activities -0.4247 81.8407 75.1727 71.3612 28.422
    Financing Cash Flow Items 0
    Issuance (Retirement) of Stock, Net -0.4247 81.8407 75.1727 71.3612 28.422
    Foreign Exchange Effects -0.00192 -0.02556 -0.0379 -0.02134 -0.00656
    Net Change in Cash -18.0912 -24.8144 -49.1555 -30.0419 -12.1343
    Issuance (Retirement) of Debt, Net 0
    Deferred Taxes
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.4859 20067883 1833565 2023-06-30 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 2.8358 7602133 983289 2023-06-30 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 2.2258 5966835 -13954601 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 2.0279 5436281 2795981 2023-06-30 HIGH
    Millennium Management LLC Hedge Fund 1.9921 5340253 5340253 2023-06-30 HIGH
    Jane Street Capital, L.L.C. Research Firm 1.1922 3196081 2261961 2023-06-30 HIGH
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.1191 3000096 -64550 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.0673 2861243 -2315538 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.8909 2388228 2367628 2023-06-30 HIGH
    Kim (Jong Joseph Ph.D.) Individual Investor 0.8751 2346000 0 2023-03-17 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.801 2147319 969218 2023-06-30 HIGH
    GMT Capital Corp. Hedge Fund 0.5646 1513500 1513500 2023-06-30 LOW
    Charles Schwab Investment Management, Inc. Investment Advisor 0.4704 1260963 -501449 2023-06-30 LOW
    Qube Research & Technologies Ltd Hedge Fund 0.3522 944190 549920 2023-06-30 HIGH
    Weiner (David B) Individual Investor 0.3466 929124 19000 2023-05-16 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3273 877447 -27034933 2023-06-30 LOW
    Susquehanna International Group, LLP Investment Advisor 0.2825 757413 -115730 2023-06-30 HIGH
    BofA Global Research (US) Research Firm 0.2499 669960 -2850667 2023-06-30 LOW
    Y-Intercept (Hong Kong) Ltd Investment Advisor 0.2364 633613 633613 2023-06-30 HIGH
    Tudor Investment Corporation Hedge Fund 0.2065 553484 418664 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Inovio Pharmaceuticals Company profile

    Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system''s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
    Industry: Biotechnology & Medical Research (NEC)

    6769 Mesa Ridge Rd.
    92121

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    ETH/USD

    1,672.82 Price
    +0.150% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Oil - Crude

    90.04 Price
    -1.230% 1D Chg, %
    Long position overnight fee 0.0661%
    Short position overnight fee -0.0881%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    XRP/USD

    0.52 Price
    -3.290% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    BTC/USD

    26,970.35 Price
    +0.080% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading